Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”-Reference-Cited by-同舟云学术

Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”

Published:2024-06 Issue:6 Volume:5 Page:101595
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Lim Bora^ORCID,Seth Sahil,Yam Clinton,Huo Lei,Fujii Takeo,Lee Jangsoon,Bassett Roland,Nasser Sara,Ravenberg Lisa,White Jason,Clayborn Alyson,Guerra Gil,Litton Jennifer K.,Damodaran Senthil,Layman Rachel,Valero Vicente,Tripathy Debasish,Lewis Michael,Dobrolecki Lacey E.,Lei Jonathan,Candelaria Rosalind,Arun Banu,Rauch Gaiane,Zhao Li,Zhang Jianhua,Ding Qingqing,Symmans W. Fraser,Chang Jeffrey T.,Thompson Alastair M.,Moulder Stacy L.,Ueno Naoto T.

Publisher

Elsevier BV

Reference37 articles.

1. Pembrolizumab for Early Triple-Negative Breast Cancer;Schmid;N. Engl. J. Med.,2020

2. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer;Liedtke;J. Clin. Oncol.,2008

3. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial;Bonnefoi;Ann. Oncol.,2014

4. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer;Chen;Ann. Surg Oncol.,2015

5. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype;Symmans;J. Clin. Oncol.,2017